[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sci---spinal-cord-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sci---spinal-cord-injury":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,47,84,112,139,159,189,207,232,256,285,303,324,355,382,412,431,450,476,500],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100581646","phase-1-double-dose-4-ap-on-functional-recovery-after-spinal-cord-injury-100581646",false,"NCT06853015","Double Dose 4-AP on Functional Recovery After Spinal Cord Injury","Effects of Twice-daily Dosing 4-AP on Functional Recovery After Spinal Cord Injury","Inclusion Criteria:\n\n* Male and females between ages 18-85 years\n* SCI 6 months post injury\n* Spinal Cord injury at or above L2\n* ASIA A, B, C, or D, complete or incomplete\n* The ability to perform a small visible contraction with dorsiflexion and hip flexor muscles\n\nExclusion Criteria:\n\n* Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease\n* Any history of renal impairment\n* Any debilitating disease prior to the SCI that caused exercise intolerance\n* Premorbid, ongoing major depression or psychosis, altered cognitive status\n* History of head injury or stroke\n* Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication\n* History of seizures or epilepsy\n* Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold (see appendix 2)\n* Pregnant females\n* If a women of child bearing age is unsure of the pregnancy, and does not want to take the pregnancy test\n* Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida, MS, or herniated disk\n* Metal plate in skull\n* Individuals with scalp shrapnel, cochlear implants, or aneurysm clips\n* Individuals taking Bupropion, Dolutegravir, Lacosamide, Trilaciclib, or PR Interval prolonging drugs","ALL","18 Years","85 Years",{"count":20,"type":21},27,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.",[28],"SCI - Spinal Cord Injury",[30,31,32,33],"spinal cord injury","neurostimulation","4-AP","rehabilitation","RECRUITING","2026-06-02",{"date":37,"type":38},"2026-06-03","ACTUAL",{"date":40,"type":38},"2025-02-01",{"date":42,"type":21},"2026-12-30",{"name":44,"class":45},"Shirley Ryan AbilityLab","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":67,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100488290","nerve-transfer-surgery-to-restore-upper-limb-function-after-cervical-spinal-cord-injury-100488290","NCT05638191","Nerve Transfer Surgery to Restore Upper-limb Function After Cervical Spinal Cord Injury","Inclusion Criteria:\n\n* Traumatic, motor-complete cervical SCI (AIS A or B)\n* Male or female, ages 18-70\n* Consent and plan to undergo nerve transfer to restore grasp function in at least one limb\n* Motor grade 4-5 at C5\n* Motor grade 0-1 at C8\u002FT1\n* Injury duration within 6 months at the time of surgery\n* English-speaking and cognitively intact\n* Able to provide informed written consent\n* Able to attend and comply with the testing protocols\n\nExclusion Criteria:\n\n* Inability or unwillingness to participate in post-operative rehabilitation (in person or virtual)\n* Secondary complication of SCI (e.g., intractable neuropathic pain, edema, contracture) or major medical comorbidity (e.g., traumatic brain injury) that would independently influence response to surgery or ability to participate in rehabilitation","70 Years",{"count":55,"type":21},40,"2 Years","OBSERVATIONAL","The goal of this prospective, open-label cohort study is to assess functional outcomes in individuals with cervical spinal cord injury who have undergone nerve transfer surgery to restore upper limb function. The main questions it aims to answer are:\n\n* Does nerve transfer improve hand function in individuals with cervical spinal cord injury?\n* What factors are associated with functional improvement following nerve transfer? Researchers will compare functional outcomes at 24 months post-surgery to 1) baseline outcomes and 2) individuals with cervical spinal cord injury who did not undergo nerve transfer.\n\nParticipants who have received nerve transfer surgery as part of their regular medical care will complete functional hand tests, electrodiagnostic assessments, and questionnaires on independence and mood every 3 months for 24 months after surgery.",[60,61,28,62,63,64,65,66],"Spinal Cord Injury","Spinal Cord Injury at C5-C7 Level","Upper Extremity Paralysis","Upper Extremity Dysfunction","Tetraplegia","Upper Extremity Paresis","Cervical Spinal Cord Injury",[30,68,69,70,71,72,73],"upper extremity nerve transfer","nerve transfer","SCI","nerve reconstruction","quadriplegia","paresis","2026-05-27",{"date":76,"type":38},"2026-05-29",{"date":78,"type":38},"2021-06-03",{"date":80,"type":21},"2028-01",{"name":82,"class":45},"University of British Columbia",4,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":46},"100339334","ecog-bmi-for-motor-and-speech-control-100339334","NCT03698149","ECoG BMI for Motor and Speech Control","A High-Performance ECoG-based Neural Interface for Communication and Neuroprosthetic Control","BRAVO","Inclusion Criteria:\n\n1. Age \\> 21\n2. Limited ability to use upper limbs, based on neurological examination, due to stroke, amyotrophic lateral sclerosis (ALS), multiple sclerosis, cervical spinal cord injury, brainstem stroke, muscular dystrophy, myopathy or severe neuropathy.\n3. Disability, defined by a 4 or greater score on the Modified Rankin Scale, must be severe enough to cause loss of independence and inability to perform activities of daily living.\n4. If stroke or spinal cord injury, at least 1 year has passed since onset of symptoms\n5. Must live within a two-hour drive of UCSF\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding\n2. Inability to understand and\u002For read English\n3. Inability to give consent\n4. Dementia, based on history, physical exam, and MMSE\n5. Active depression (BDI \\> 20) or other psychiatric illness (active general anxiety disorder, schizophrenia, bipolar disorder, obsessive-compulsive disorder (OCD), or personality disorders (e.g. multiple personality disorder, borderline personality disorder, etc.)\n6. History of suicide attempt or suicidal ideation\n7. History of substance abuse\n8. Co-morbidities including ongoing anticoagulation, uncontrolled hypertension, cancer, or major organ system failure\n9. Inability to comply with study follow-up visits\n10. Any prior intracranial surgery\n11. History of seizures\n12. Immunocompromised\n13. Has an active infection\n14. Has a CSF drainage system or an active CSF leak\n15. Requires diathermy, electroconvulsive therapy (ECT), or transcranial magnetic stimulation (TMS) to treat a chronic condition\n16. Has an implanted electronic device such as a neurostimulator, cardiac pacemaker\u002Fdefibrillator or medication pump, or presence of any head or neck metallic foreign bodies\n17. Allergies or known hypersensitivity to materials in the Blackrock NeuroPort Array (i.e. silicone, titanium) or the PMT Subdural Cortical Electrode (silicone, platinum iridium, nichrome)","21 Years",{"count":94,"type":21},3,[96],"NA","Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.",[99,28,100,101,102],"ALS","Stroke","Multiple Sclerosis","Muscular Dystrophies","2026-04-30",{"date":105,"type":38},"2026-05-05",{"date":107,"type":38},"2018-11-09",{"date":109,"type":21},"2030-08-15",{"name":111,"class":45},"Karunesh Ganguly",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":46},"100617378","home-based-heat-therapy-in-spinal-cord-injury-to-improve-cardiovascular-health-100617378","NCT07317843","Home-Based Heat Therapy in Spinal Cord Injury to Improve Cardiovascular Health","Home-Based Passive Heat Therapy-Towards a Scalable Intervention to Improve Cardiovascular Health in Persons With Spinal Cord Injury","IIS_SCIDoD","Inclusion Criteria:\n\n1. Participant demonstrates understanding of the study and has provided an appropriately signed and dated informed consent.\n2. Participants will be male or female, 18-60 years of age, at the time of Visit 0.\n3. Female participants must be non-lactating. Female patients are eligible only if they have a negative pregnancy test throughout the study period (or are postmenopausal). Postmenopausal women taking hormone replacement will be included if they have been on a stable dose for =6 months.\n4. Stable SCI (AIS A or B) of longer than 1-year duration.\n5. Use of medications for clinical management of medical problems directly related to SCI is not considered an exclusion criterion. Status such as detrusor instability, muscle spasms, and other common SCI problems (other than those that could alter vascular responsiveness) may be allowed for those SCI participants who have been on stable doses for =6 months. Results from participants taking such medications will be analyzed to determine possible medication-related differences from those on no medications.\n\nExclusion Criteria:\n\n1. Participants who smoke, or:\n2. Uses daily administration of anti-inflammatory medications (stable doses of NSAIDs or statins are acceptable; steroids are exclusionary)\n3. Uses daily administration of vasoactive medications (e.g., alpha antagonists or agonists or phosphodiesterase inhibitors).\n4. Has a current pressure ulcer or skin breakdown.\n5. Has an active, uncontrolled, autoimmune or inflammatory disorder\n6. Has no history of or current alcohol or substance use disorder\n7. Has a history of heat related illness (e.g., heat stroke)\n8. Has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study. This includes, but is not limited to, a clinically relevant medical or surgical history.\n9. Is unlikely to cooperate with the requirements of the study.","60 Years",{"count":122,"type":21},48,[96],"The study is designed to investigate the effects of passive heat therapy on blood vessel health in 40 people (48 enrolled with attrition rate of 20%). Following an extensive set of vascular function tests, participants will engage in either a passive heat therapy intervention for 60 minutes, 4 times a week for 8 weeks, or a placebo intervention at a lower temperature. Seven of the 8 weeks of intervention will occur in the home setting. Vascular function tests will be repeated after the 8 weeks to determine if chronic passive heat stress improved vascular health.",[28],[70,127,128,129,130],"heat therapy","heat stress","passive heat","vascular function","2026-04-28",{"date":105,"type":38},{"date":134,"type":38},"2026-03-24",{"date":136,"type":21},"2031-07",{"name":138,"class":45},"The University of Texas Health Science Center at San Antonio",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":145,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":157,"locationsCount":46},"100554051","a-novel-repetitive-synchronized-associative-stimulation-neuromodulation-approach-for-spinal-cord-injury-patients-100554051","NCT06494059","A Novel Repetitive Synchronized Associative Stimulation Neuromodulation Approach for Spinal Cord Injury Patients","Inclusion Criteria:\n\nMale or Female subjects\n\n1. At least 18 years old and no older than 70 years old at the time of enrollment.\n2. Able-bodied subjects\n3. Traumatic spinal cord injury\n4. Upper limb target: neurological level at or above Thoracic 1 level, Abbreviated Injury Scale (AIS) B, C or D impairment grade, primary non-ambulatory;\n\n   * Lower limb target: neurological level at or above Thoracic 10 level, with residual lower limb function; AIS B, C or D impairment grade primary could ambulate;\n   * Trunk target: neurological at or above Thoracic 5, AIS A, B, C or D impairment grade, primary wheelchair user\n5. Spinal cord injury sustained more than 6 months prior to study.\n6. Movement\u002Fexcitability\u002Fetc:\n\n   * Upper limb target: Has detectable residual connection in upper-limb muscles in at least one side confirmed by voluntary electromyography (EMG) or detectable motor evoked potential (MEP) and a visible contraction when functional electrical stimulation (FES) is applied in the hand or wrist muscle at baseline.\n   * Lower limb target: Has detectable residual connection in lower-limb muscles in at least one side confirmed by voluntary EMG or detectable MEP and a visible contraction when FES is applied in lower limb ankle plantar or dorsiflexor muscle at baseline.\n   * Trunk target: Has detectable residual connection in trunk muscles in at least one side confirmed by voluntary EMG or detectable MEP and a visible contraction when FES is applied in trunk muscle at baseline.\n7. Able to commit to intervention and assessment sessions over a maximum duration of 2 months.\n\nExclusion Criteria:\n\n1. Has traumatic brain injury, stroke, multiple sclerosis, or other disorders that could affect neuromotor function.\n2. Has severe spasticity that could prevent the study protocol as determined by the investigator.\n3. Has major executive dysfunction, dementia, depression, neurocognitive impairments, or other major medical co-morbidities.\n4. Has contraindications for transcutaneous stimulation using FES or TSCS such as breakdown of skin in the area that will come into contact with electrodes, thrombosis, or skin disease.\n5. Has a poorly managed autonomic dysreflexia that could be triggered by transcranial magnetic stimulation (TMS), FES, or TSCS.\n6. Has a history of prior intracranial surgery or known medical risks that would limit TMS protocols.\n7. Has a history of epilepsy, convulsion or seizures.\n8. Individuals with metal implants in their head or spine near the sites to be stimulated and other implantable devices (e.g., cochlear implants) in the body that could be affected by TMS or TSCS.\n9. Has implanted neurostimulator (e.g., deep brain stimulation (DBS), epidural\u002Fsubdural, vagal nerve stimulation or VNS).\n10. Has a cardiac pacemaker or intracardiac lines.\n11. Has peripheral neuropathy, including diabetic polyneuropathy and entrapment neuropathy.\n12. Has urinary tract infection, unhealed fracture, contracture, and pressure sore as determined by Braden Scale value of 14 and below.\n13. Individuals who require therapy or other care that could interfere with participation in the study.\n14. Individuals on investigational drugs or any other intervention known to have a potential impact on neuromotor function.\n15. Individuals with substance disorders, including alcoholism and drug abuse.\n16. Individuals who are pregnant, breastfeeding, or the desire to become pregnant during the study.\n17. In the opinion of the investigators, the study is not safe or appropriate for the participant.",true,{"count":147,"type":21},25,[96],"The purpose of this research is to explore the effect of magnetic stimulation to activate the brain, electrical spinal cord stimulation to activate spinal cord, and electrical muscle stimulation used to activate upper limb (arms), lower limb (legs) and trunk (stomach) muscles in people with spinal cord injury (SCI) and able-bodied subjects (without SCI).",[28],"2026-04-20",{"date":153,"type":38},"2026-04-23",{"date":155,"type":38},"2024-11-04",{"date":42,"type":21},{"name":158,"class":45},"University of Miami",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":175,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100611001","arc-im-therapy-to-support-and-promote-recovery-of-ambulatory-functions-in-people-with-subacute-and-chronic-spinal-cord-injury-100611001","NCT07234903","ARC-IM Therapy To Support and Promote Recovery of Ambulatory Functions in People With Subacute and Chronic Spinal Cord Injury","EIGER","Inclusion Criteria:\n\n1. Must be at least 18 years old and no older than 65 years old at the time of enrollment.\n2. Must be graded A, B, C, or D in the ASIA Impairment Scale (AIS).\n3. Must have a SCI level at T10 or higher as determined by ISNCSCI, with the region extending 6 cm above the tip of the conus remaining anatomically intact as determined by MRI.\n4. Must have sustained their injury either less than 6 weeks prior to baseline (Group \"Subacute SCI\"), or more than 1 year prior to enrollment (Group \"Chronic SCI\").\n5. Must be suffering from a SCI due to trauma.\n6. Must have a stable medical, physical and psychological condition as considered by the investigators and the delegated specialists.\n7. Must have residual upper limb function to use the arms for weight bearing support (as determined by functional demonstration).\n8. Must be able to understand and interact with the study team in German, French or English.\n9. Must agree to comply in good faith with all conditions of the study and to attend all scheduled appointments.\n10. Must provide Informed Consent as documented by signature prior to any study-related procedures.\n11. Must have an acceptable or highly effective method of contraception for women of childbearing capacity.\n\nExclusion Criteria:\n\n1. Must not be pregnant nor breastfeeding.\n2. Must not have brain damage.\n3. Must not have a history of epilepsy\n4. Must not have participated in another clinical study using drugs or medical devices within the 30 days preceding and during the present study.\n5. Must not have previously been injected with stem cells in the spinal cord.\n6. Must not have any diseases and conditions that would increase the morbidity and mortality of SCI surgery.\n7. Must not require ventilator support.\n8. Must not have any existing contraindication to mobility functions (e.g., unhealed bone fractures, central nervous system disorder, peripheral nerve disorder, etc.).\n9. Must not suffer from SCI from other etiology than trauma (ischemic, tumoral, autoimmune, etc.).\n10. Must not have any anatomical limitations in the implantation area as judged by the investigators (e.g., spinal stenosis, limiting protrusions, post-traumatic bone damage at area of implantation).\n11. Must not require the use of an intrathecal baclofen pump.\n12. Must not have any active implanted devices.\n13. Must not have any other conditions that would make the subject unable to participate in testing in the judgment of the investigators (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.).\n14. Must not be the investigator him\u002Fherself, his\u002Fher family members, employees or other dependent persons.","65 Years",{"count":168,"type":21},12,[96],"The EIGER study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support and promote recovery of ambulatory functions, such as walking, in people with subacute and chronic spinal cord injury.",[60,70,28,172,173,174],"Subacute Spinal Cord Injury","Chronic Spinal Cord Injury","Spinal Cord Injury (SCI)",[70,60,176,177,178],"Epidural Electrical Stimulation","Spinal Cord Stimulation","ARC-IM Therapy","2026-04-16",{"date":181,"type":38},"2026-04-21",{"date":183,"type":21},"2026-04",{"date":185,"type":21},"2032-04",{"name":187,"class":45},"Ecole Polytechnique Fédérale de Lausanne",2,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":145,"sex":195,"minAge":17,"maxAge":166,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":198,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":46},"100600938","food-intake-and-thermogenesis-in-high-spinal-cord-injury-100600938","NCT07103993","Food Intake and Thermogenesis in High Spinal Cord Injury","Inclusion Criteria:\n\nSCI and Controls\n\n* Men\n* Physically inactive (\\\u003C150 minutes per week of moderate-vigorous activity intensity for the preceding 3 months)\n* Weight stable: body mass ±3 kilograms (kg) for past 3 months\n\nSCI Only\n\n* Chronic SCI (≥ 1-year post-injury)\n* Motor-complete SCI American Spinal Injury Association Impairment Scale (AIS) A and B\n* T6 injuries and above that can independently feed themselves\n\nExclusion Criteria:\n\nSCI and Controls\n\n* Uncompensated thyroid disease\n* Diabetes\n* Swallowing or gastrointestinal pathologies\n* Allergies or aversions to foods\u002Fingredients\n* Prescribed prokinetic, antipsychotic, or anti-obesity agents\n\nSCI Only\n\n* Incomplete SCI AIS C or D\n* Ventilator-dependent","MALE",{"count":197,"type":21},56,[96],"The purpose of this research is to determine the effects of food on cardiovascular and metabolic health in men with and without spinal cord injury (SCI).",[28],{"date":181,"type":38},{"date":203,"type":38},"2026-03-13",{"date":205,"type":21},"2027-12-31",{"name":158,"class":45},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":214,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":220,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":46},"100493461","epidural-stimulation-after-neurologic-damage-long-term-outcomes-100493461","NCT05705453","Epidural Stimulation After Neurologic Damage: Long-Term Outcomes","LTO","Inclusion Criteria:\n\n* 22 years of age or older\n* Able to undergo the informed consent process\n* Stable spinal cord injury\n* International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) neurologic level of injury below C5\n* No ventilator dependency within the last year\n* American Spinal Injury Association (AISA) imparement scale\"A\" or \"B\" in the absence of spinal cord stimulation\n* Medically stable in the judgment of the Principal investigator\n* Greater than 1 year since initial injury and at least 6 months from any required spinal instrumentation and 2 months from spinal cord stimulator surgery\n* Has an existing and functional implanted spinal cord stimulator system that is FDA approved and can be corroborated by hospital documentation\n* Spinal imaging of the stimulator system\n\nExclusion Criteria:\n\n* Current and anticipated need for opioid pain medications or pain that would prevent full participation in the rehabilitation program in the judgment of the principal investigator\n* Use of botulinum toxin (Botox) injections in the previous six months\n* Clinically significant mental illness in the judgment of the principal investigator\n* Other conditions or medications that would make the subject unable to participate in testing\u002Frehabilitation in the judgment of the principal investigator\n* Nonfunctional spinal cord stimulator or near end-of-life, determined by the PI\n* Current Pregnancy\n* Current pain relief from the spinal cord stimulator if the indication for implantation was for management of chronic pain.","22 Years",{"count":216,"type":21},50,[96],"This study will evaluate the long-term effect of chronic spinal cord stimulation to restore volitional movement for patients with chronic spinal cord injuries.",[28],[221,222],"spinal cord stimulation","epidural stimulation","2026-04-02",{"date":225,"type":38},"2026-04-08",{"date":227,"type":38},"2023-05-11",{"date":229,"type":21},"2034-04-01",{"name":231,"class":45},"University of Minnesota",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":120,"enrollmentInfo":240,"targetDuration":4,"studyType":22,"phases":242,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":46},"100632250","scs-therapy-for-patients-with-bladder-and-bowel-dysfunction-after-sci-100632250","NCT07511244","SCS Therapy for Patients With Bladder and Bowel Dysfunction After SCI","Clinical Trial on the Safety and Efficacy of Spinal Cord Stimulation Therapy for Patients With Bladder and Bowel Dysfunction After Spinal Cord Injury","SCSBBD","Inclusion Criteria:\n\n* Age: 18 to 60 years old\n* Spinal Cord Injury Classification: AIS Grade A, B, C, or D\n* Injury Duration: \\> 6 months\n* Stable and healthy condition, as determined by the investigator; able to complete the entire study period and cooperate with examinations\n* Voluntary participation in clinical trial and ability to sign informed consent form\n* Good patient compliance, willing and able to follow follow-up requirements during the follow-up period\n\nExclusion Criteria:\n\n* Mental Disorders Patients with obvious mental illnesses (such as anxiety, depression, etc.) who are unable to complete relevant subjective scoring.\n* Mental and Cognitive Impairments Patients with mental or cognitive disorders who are unable to cooperate with surgeries, undergo programming procedures, or complete follow - up.\n* Autonomic Reflex Disorders Patients with severe autonomic reflex disorders.\n* Inability in Surgical and Follow - up Processes Patients who are unable to undergo spinal cord stimulation surgery or cooperate with follow - up.\n* Spinal Abnormalities Patients accompanied by progressive spinal instability or severe spinal deformities.\n* Life Expectancy Patients with an expected lifespan of less than one year.\n* Laboratory Abnormalities and Surgical Tolerance Patients with abnormal blood routine, blood biochemistry, etc., and are clinically judged to be unable to tolerate surgery, such as those with coagulation disorders, abnormal liver and kidney function.\n* Cardiovascular and Respiratory Diseases Patients with uncontrolled hypertension, severe heart diseases, or severe internal medicine and respiratory system diseases, or those who have regularly taken medications related to hypertension and heart diseases within the recent three months.\n* Renal Disorders Patients with severe hydronephrosis or renal function disorders.\n* Urogenital Function Disorders before Spinal Cord Injury Patients with pre - existing urethral sphincter or bladder dysfunction before spinal cord injury.\n* History of Pelvic Surgery and Radiotherapy Patients with a history of pelvic radiotherapy, bladder cancer, or other bladder surgeries that affect the basic bladder physiology.\n* Other Inappropriate Cases Patients considered inappropriate by the researchers.",{"count":241,"type":21},10,[96],"This clinical trial aims to evaluate the safety and efficacy of spinal cord stimulation (SCS) in treating patients with urinary and bowel dysfunction after spinal cord injury (SCI). SCI is a highly disabling condition that can lead to sensory, motor, and autonomic nervous system dysfunction below the injury level. Neurogenic bladder and bowel dysfunction are common sequelae of SCI, seriously affecting patients' quality of life. Currently, clinical treatments can only partially alleviate urinary and bowel dysfunction, and more effective therapeutic approaches are still needed. Existing clinical studies have shown that SCS is gradually being applied to treat neurogenic bladder and bowel dysfunction in SCI patients. SCS can significantly improve urinary efficiency, bladder capacity, compliance, and detrusor pressure in SCI patients, thereby enhancing their quality of life. The main questions this study aims to answer include: 1. Can this protocol help patients restore partial urinary and bowel function? 2. Besides the restoration of partial urinary and bowel function , can the SCS therapy could also help patients to restore the walking function.\n\nPatients with urinary and bowel dysfunction more than 6 months after spinal cord injury will undergo epidural spinal stimulation electrode implantation surgery two weeks after functional assessment. Then the parameter optimization and rehabilitation will last for 6 months. The follow-up records and assessments will be conducted monthly at 2, 4, and 6 months after surgery.",[245,28],"Bladder and Bowel Dysfunction",[245,60],"2026-03-30",{"date":249,"type":38},"2026-04-06",{"date":251,"type":38},"2024-12-01",{"date":253,"type":21},"2029-12-31",{"name":255,"class":45},"Beijing Tsinghua Chang Gung Hospital",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":262,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":46},"100544013","the-effect-of-a-muscle-mimicking-fabric-type-shoulder-orthosis-on-functional-movements-of-the-upper-limb-in-patients-with-neuromuscular-disorder-100544013","NCT06363357","The Effect of a Muscle-mimicking, Fabric-type Shoulder Orthosis on Functional Movements of the Upper Limb in Patients With Neuromuscular Disorder","Inclusion Criteria\n\n1. Patients with a confirmed diagnosis of a neuromuscular disease (NMD) by genetic testing, muscle biopsy, or electrodiagnostic studies, presenting with prominent upper limb muscle weakness. Examples include:\n\n   1. Muscular Dystrophies: Duchenne\u002FBecker Muscular Dystrophy (DMD\u002FBMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD), etc.\n   2. Motor Neuron Diseases: Spinal Muscular Atrophy (SMA, Types 2 and 3), Amyotrophic Lateral Sclerosis (ALS, upper limb-dominant), etc.\n   3. Peripheral Neuropathies: Charcot-Marie-Tooth (CMT) disease, etc.\n   4. Other Neuromuscular Conditions: Including but not limited to cervical spinal cord injury.\n2. Aged over 10 years.\n3. A score of 2 to 5 on the Brooke Upper Extremity Functional Rating Scale.\n4. Manual Muscle Test (MMT) grade of less than 3 for shoulder abduction.\n5. Ability to provide written informed consent from the participant and\u002For their legal representative, indicating willingness to participate in the study.\n\nExclusion Criteria\n\n1. Unwillingness or inability to provide informed consent.\n2. A score of 1 or 6 on the Brooke Upper Extremity Functional Rating Scale.\n3. Cognitive impairment severe enough to interfere with the proper use of a shoulder orthosis.\n4. Any other condition which, in the opinion of the investigator, would make study participation inappropriate or unsafe for the patient.","10 Years",{"count":264,"type":21},30,[96],"The goal of this clinical trial is to investigate the effect of a muscle-mimicking, fabric-type shoulder orthosis on functional movements of the upper limb in patients with neuromuscular disorder.\n\nThe main questions it aims to answer are:\n\n* What is the impact of the muscle-mimicking, fabric-type shoulder orthosis on upper limb functional movements in patients with neuromuscular disorder?\n* Are there observable differences in upper limb function when the shoulder orthosis is worn versus when it is not?\n\nParticipants will:\n\n* Receive education on how to wear and use the shoulder orthosis.\n* Undergo evaluations, including assessment of upper limb performance, shoulder muscle strength testing, active range of motion measurements, assessment of functional workspace, goal attainment scale evaluation, surface electromyography, physiological measurements such as blood pressure and heart rate, fatigue assessment, and assessment for any musculoskeletal or skin-related issues.\n\nResearchers will compare neuromuscular disorder patients before and while wearing and operating the shoulder orthosis to see if there are any significant effects on variables such as upper limb function, range of motion, functional workspace, goal attainment scale, and surface electromyography.",[268,269,270,271,272,273,274,275,28],"Muscular Dystrophy, Duchenne","Orthotic Devices","Upper Extremity","Neuromuscular Diseases (NMD)","Fascioscapulohumeral Muscular Dystrophy","Spinal Muscular Atrophy (SMA)","ALS (Amyotrophic Lateral Sclerosis)","LGMD","2025-11-25",{"date":278,"type":38},"2025-12-03",{"date":280,"type":38},"2024-04-20",{"date":282,"type":21},"2025-12-31",{"name":284,"class":45},"Seoul National University Hospital",{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":145,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":293,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":46},"100596966","gut-brain-neural-coupling-in-spinal-cord-injury-100596966","NCT07052344","Gut-Brain Neural Coupling in Spinal Cord Injury","Inclusion Criteria, SCI and Controls\n\n* Adults, 18 to 70 years of age.\n* Sex, male or female.\n* Weight-stable (±3 kg) for the preceding 3 months (self-report).\n* Physically inactive adults not meeting weekly activity guidelines (\\\u003C150 min\u002Fweek) for the preceding 3 months (self-report).\n* Fluent in written and spoken English.\n\nExclusion Criteria, SCI and Controls\n\n* Do not meet the inclusion criteria.\n* Current\u002Fregular smoker (defined by Center for Disease Control (CDC)\u002F National Institute of Health (NIH) as an adult who has smoked 100 cigarettes in his or her lifetime and who currently smokes either every day or every other day) (self-report).\n* Currently dieting and\u002For trying to gain or lose weight.\n* Vagus or recurrent laryngeal nerve injury (self-report).\n* Uncontrolled thyroid disease, such that they are not on thyroid medication (e.g., levothyroxine) to treat the condition (self-report)\n* Diabetes (type 1 or type 2) and\u002For currently taking anti-diabetic or glucagon-like peptide-1 (GLP-1)\u002Fdual agonist medications (self-report).\n* Gastrointestinal disease (self-report), such as inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis), celiac disease, irritable bowel syndrome, gastroesophageal reflux disease, peptic ulcer disease, chronic pancreatitis, liver cirrhosis, and any condition requiring gastrointestinal surgery (e.g., bowel resection, colostomy, or ileostomy).\n* Swallowing disorder (self-report).\n* History of bariatric surgery\n* Food allergies\u002Fdislikes or dietary restrictions (i.e. vegan) (self-report).\n* Allergy to adhesives (self-report)\n* Open abdominal wounds or abdominal skin not intact.\n* Current use of probiotics\u002Fprebiotics (self-report).\n* Current use of medications that can impact appetite, body weight, and\u002For bowel function, such as prokinetic, antiemetic, narcotic analgesics, anticholinergic, anti-inflammatory, antipsychotic, or anti-obesity agents (self-report).\n* Pregnant (determined by urine pregnancy test) or breastfeeding women.\n* Non-adults (infants, children, teenagers).\n* Adults unable to consent\n* Prisoner.\n\nSCI-specific Eligibility Criteria\n\nInclusion Criteria, SCI Only\n\n* At least 12 months post-SCI, denoting chronic injury\n* Complete American Spinal Injury Association (ASIA) Impairment Scale (AIS A) or motor-incomplete (AIS B) tetraplegia (SCI at or above C8 lesion)\n* Able to self-feed (self-report)\n* On a bowel care program every day or every other day (self-report).\n\nExclusion Criteria, SCI Only\n\n* Under 12 months post-SCI.\n* Motor-incomplete (AIS C, D) paraplegia (SCI below C8 lesion), including thoracic, lumbar, and sacral injuries.\n* Ventilator-dependence (self-report).",{"count":292,"type":21},28,[96],"The purpose of this research is to determine the effects of food on brain and stomach activity in persons with and without spinal cord injury (SCI).",[28],"2025-11-19",{"date":276,"type":38},{"date":299,"type":38},"2025-10-29",{"date":301,"type":21},"2026-12-31",{"name":158,"class":45},{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":312,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":46},"100542943","the-utilization-effects-of-powered-wearable-orthotics-in-improving-upper-extremity-function-and-adl-in-persons-with-sci-100542943","NCT06349434","The Utilization Effects of Powered Wearable Orthotics in Improving Upper Extremity Function and ADL in Persons With SCI","Inclusion Criteria:\n\n* Be between ages 18-80\n* Be able to activate certain muscles in my arm and forearm on my own a sufficient amount as measured by EMG amplitude. This will be determined by the study OT\u002FPT.\n* Be diagnosed with spinal cord injury (SCI) with level C1-C8 and ASIA Impairment Scale (AIS) C or D, as determined by study staff. If I have not had an exam to determine my injury level and impairment scale recently, I may participate in an examination of my sensation and strength in my arms, legs, trunk and rectum as was done in the hospital soon after my injury.\n* Be at least 1-year post injury\n* Have sufficient ability to move my shoulder (active shoulder flexion of 30 degrees and active shoulder abduction 20 degrees), as determined by study staff\n* Be medically stable\n* Have sufficient learning and memory abilities and abilities to communicate in English to be able to participate and follow directions during my rehabilitation\n* Continue to take all prescribed medication (e.g., oral or via pump baclofen) without any dosing changes\n* Be able to tolerate functional tasks for 60 minutes with periodic rests without excessive fatigue\n* Have minimal strength in the muscles that bend and straighten my elbow, as determined by study staff\n* Have full range of motion in my elbow when it is moved by the study therapist\n\nExclusion Criteria:\n\n* Be younger than 18 years old or older than 80\n* Have excessive pain in my arm, wrist, or hand that limits providing rehabilitation\n* Have excessive spasticity in my elbow or wrist, as determined by study staff\n* Be participating in any experimental rehabilitation or drug studies\n* Have history of nervous system disorder other than SCI\n* Have difficulty following multiple step directions\n* Have severe cognitive or psychiatric problems might be contraindications to start training.\n* Have skin issues or severe sensory deficits that would prevent wearing the Myo-Pro device safely\n* Be pregnant\n* Have other conditions or circumstances that, in the opinion of the investigators, would affect the safety or effectiveness of the training in which I would participate","80 Years",{"count":311,"type":21},60,[96],"To evaluate the usefulness of an upper extremity assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury. The Department of Defense is supporting this study.",[28,63,315],"Upper Extremity Problem",{"date":317,"type":38},"2025-11-24",{"date":319,"type":38},"2023-10-15",{"date":321,"type":21},"2028-10-01",{"name":323,"class":45},"Kessler Foundation",{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":344,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":46},"100609083","augmented-reality-bci-longitudinal-study-for-persons-with-als-stroke-tbi-and-sci-utilizing-cognixion--apple-vision-pro-100609083","NCT07209943","Augmented Reality BCI Longitudinal Study for Persons With ALS, Stroke, TBI and SCI Utilizing Cognixion + Apple Vision Pro","Cognixion Pass Through Study","Inclusion criteria:\n\n* Must have a designated on-site support individual who can be trained on the Cognixion system\n* Fluent in understanding English\n* 18 years or older\n* Must have one of ALS, spinal cord injury or chronic brain injury and need an assistive communication device\n* Must be able to engage in volitional eye opening and sustain eye opening independently for at least 30 minutes.\n* Must have a way to communicate apart from using the Cognixion device such as vocalizations, head nod, eye blinks, eyebrow raises, etc. At a minimum, reliable, independent way of communicating \"Yes\" and \"No\"\n\nExclusion criteria:\n\n* Disruption in English comprehension, either due to lack of fluent proficiency or due to a developmental\u002Facquired language disorder (e.g. aphasia)\n* Severely hearing impaired or deaf\n* Sensitivity to flashing lights\n* Claustrophobia related to the Apple Vision Pro with comfort adapter\n* History of epilepsy and\u002For seizures\n* Vision disorders restricting the visual field such as glaucoma, diplopia (double vision), nystagmus (involuntary eye movements)\n* History of vertigo or other vestibular disorders\n* Scalp that is prone to irritation, inflammation, injury, or infectious process",{"count":241,"type":21},[96],"The goal of this study is refine the usability of a BCI capable communication platform.\n\nThe study will take place in the United States area and will enroll up to 10 participants with late stage ALS, traumatic brain injury (TBI) or spinal cord injury (SCI) that have assistive communication and computer control needs. Each subject will receive an integrated Cognixion + Apple Vision Pro device that includes an augmented reality brain computer interface and associated communication software. The study duration is 3-4 months for each participant.\n\nThe key questions that will be addressed in this study are:\n\n1. Identify the ability of individuals with target indications to use the integrated Cognixion-Apple Vision Pro system to communicate effectively.\n2. Identify the ability of such individuals to learn to use BCI, ET-BCI and other modalities, and to measure their progress over time.\n3. Identify the effectiveness of the different forms of input supported by the combined Cognixion-Apple Vision Pro system (BCI, eye-tracking) in allowing such individuals to communicate and have agency.\n4. Identify how input such as BCI can be optimized to suit the needs of individuals (e.g., specific frequencies that work best for an individual, SNR with different frequencies, number of targets, length of recording for each frequency) and improve overall usability.\n5. Identify the extent to which personalization through a large language model (LLM) affects communication.\n6. Identify the appropriate capabilities to enable through an agentic communication interface.\n\nKey measures include:\n\nITR - information transfer rate SUS - system usability scale",[274,335,28,100],"TBI Traumatic Brain Injury",[337,338,339,340,341,342,30,343],"usability study","augmented reality","brain computer interface","als","generative AI","agentic","traumatic brain injury","NOT_YET_RECRUITING","2025-09-29",{"date":347,"type":38},"2025-10-07",{"date":349,"type":21},"2025-10-16",{"date":351,"type":21},"2026-05-31",{"name":353,"class":354},"Cognixion","INDUSTRY",{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":362,"enrollmentInfo":363,"targetDuration":4,"studyType":22,"phases":365,"briefSummary":366,"conditions":367,"keywords":370,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":46},"100601097","near-infrared-imaging-of-motor-imagery-effects-in-spinal-cord-injury-100601097","NCT07106060","Near-Infrared Imaging of Motor Imagery Effects in Spinal Cord Injury","A Near-Infrared Functional Imaging Study on Motor Imagery Training in Patients With Spinal Cord Injury","Inclusion Criteria:\n\n1. The vital signs are stable and the spine is stable, making the subject suitable for exercise testing.\n2. Patients with spinal cord injury (SCI) who meet the international diagnostic criteria for SCI neurology revised by the American SCI Society in 2019 and have been diagnosed by CT or MRI.\n3. The injury level of SCI is C5-T12, and the ASIA grade is A-C.\n4. The course of the disease is ≤12 months (but the spinal shock period must have passed).\n5. Age: 18-75 years old, regardless of gender.\n6. Good cognitive function, able to understand and actively participate in the training program, and willing to sign the informed consent form for this clinical study.\n\nExclusion Criteria:\n\n1. Those with tumors, tuberculosis, hematologic diseases, or dysfunction of important organs such as the heart and liver;\n2. Those with unstable fractures;\n3. Those with severe abnormal limb muscle tone and joint contracture deformities;\n4. Those with severe pain that cannot tolerate activities;\n5. Those with severe emotional problems who cannot cooperate to complete the study.","75 Years",{"count":364,"type":21},36,[96],"The primary objective of this clinical trial is to investigate the efficacy of motor imagery-based brain-computer interface (MI-BCI) technology in improving motor function among patients with spinal cord injury (SCI), as well as its impact on cortical motor area function across varying states. To achieve this, the study will implement MI-BCI intervention in SCI patients, evaluate post-treatment motor function improvements, and assess changes in cortical motor area oxygen metabolism (via functional near-infrared spectroscopy, fNIRS) and neural activity (via electroencephalography, EEG). The ultimate goal is to establish a novel rehabilitation strategy for SCI.\n\nSpecifically, the trial aims to: (1) determine whether MI-BCI effectively enhances motor function in SCI patients; and (2) clarify the differential effects of MI-BCI on cortical motor area function under distinct states (e.g., resting vs. task-performing) in this population.\n\nParticipants will be randomly assigned to one of two groups: the experimental group will undergo MI-BCI training, while the control group will receive active cycling training (as a conventional rehabilitation control). Both interventions will be structured as 20-minute sessions, administered 5 days per week, over a total of 4 weeks.Pre- and post-treatment assessments will include: lower limb motor function (measured by the Lower Limb Motor Score), activities of daily living (evaluated via the Modified Barthel Index), walking capacity (quantified using the Spinal Cord Injury Walking Index), and cortical motor activity (captured through fNIRS and EEG measurements).",[28,368,369],"Motor Imagery","Brain-Computer Interfaces",[28,371,369,372],"motor imagery","Functional near-infrared spectroscopy","2025-07-30",{"date":375,"type":38},"2025-08-06",{"date":377,"type":38},"2025-01-01",{"date":379,"type":21},"2026-02-01",{"name":381,"class":45},"Shengjing Hospital",{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":145,"sex":16,"minAge":17,"maxAge":388,"enrollmentInfo":389,"targetDuration":4,"studyType":22,"phases":391,"briefSummary":392,"conditions":393,"keywords":399,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":46},"100592899","phase-1-exploring-the-utility-of-18f3f4ap-for-demyelination-imaging-100592899","NCT06999434","Exploring the Utility of [18F]3F4AP for Demyelination Imaging","Inclusion:\n\n1. Male and Female subjects must be ≥18 and \\\u003C90 years of age;\n2. Able to understand and provide informed consent prior to study procedures\n3. Must be in good health\n\nExclusion:\n\n1. Less than 18 years of age;\n2. Pregnant or breastfeeding;\n3. Any significant systemic illness or unstable medical condition;\n4. Pre-existing medical conditions or claustrophobic reactions;\n5. Research-related radiation exposure exceeds current PET Center guidelines (i.e. 50 mSv in the prior 12 months);\n6. History of a bleeding disorder or are currently taking anticoagulants.","90 Years",{"count":390,"type":21},105,[24],"The overall objective is to obtain an assessment of the pharmacokinetics of \\[18F\\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).",[394,395,396,397,28,398],"Demyelinating Disorders","MCI","Alzheimer's Disease (AD)","MS (Multiple Sclerosis)","Spinal Radiculopathy",[400,394,401,70,402],"3F4AP","MS","AD","2025-05-22",{"date":405,"type":38},"2025-05-31",{"date":407,"type":38},"2025-05-05",{"date":409,"type":21},"2030-05-05",{"name":411,"class":45},"Yale University",{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":22,"phases":419,"briefSummary":420,"conditions":421,"keywords":422,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":430,"locationsCount":46},"100566055","improving-balance-after-spinal-cord-injury-using-a-robotic-upright-stand-trainer-and-spinal-cord-epidural-stimulation-100566055","NCT06650202","Improving Balance After Spinal Cord Injury Using a Robotic Upright Stand Trainer and Spinal Cord Epidural Stimulation","Inclusion Criteria:\n\n* At least 18 years old\n* Stable medical condition.\n* Has a spinal cord injury caused by trauma (fall, car accident, etc.) for at least one year that is not getting worse over time\n* Has an implanted spinal cord epidural stimulation unit that is eligible for software upgrade as part of a previous study.\n* Unable to stand independently with epidural stimulation turned off.\n\nExclusion Criteria:\n\n* unwilling to discontinue from anti-spasticity medications\n* Untreated painful problems with joints, muscles or bones.\n* Unhealed fracture.\n* Pressure sore or urinary tract infection.\n* History of bone disease (except for decreased bone mineral density due to spinal cord injury).\n* Ongoing drug abuse.\n* Untreated psychiatric disorders or clinical depression.\n* Received Botox injections in the lower extremities in the prior six months.\n* Heart or lung disease that may interfere with assessments.\n* Untreated severe and persistent problems regulating blood pressure, heart rate, body temperature or other automatic functions.",{"count":5,"type":21},[96],"The purpose of this study is to understand how standing and sitting balance control is altered after spinal cord injury and how a new type of robotic assistive device may be used with spinal stimulation to improve muscle function. The investigators will be testing a device called the Tethered Pelvic Asist Device (or \"TPAD\") in this study. The TPAD may be helpful in two ways. It can be used to help control and support of the trunk, pelvis, and knees during stand training. Also, the TPAD can be used as a training tool by providing controlled \"pushes\" or \"perturbations\" that must be corrected by the person with spinal cord injury in order to maintain proper posture and upright balance. This could be helpful for improving muscle function after spinal cord injury.\n\nParticipants will be placed into one of two groups based on availability and preference. Group 1 will receive TPAD training with stimulation and assessments with and without stimulation. Participation in this group lasts approximately 4 months. Group 2 will only receive assessments with and without stimulation. Participation in this group last approximately 3 weeks.",[28],[423],"TPAD","2025-04-28",{"date":426,"type":38},"2025-04-30",{"date":428,"type":38},"2024-11-01",{"date":80,"type":21},{"name":323,"class":45},{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":145,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":22,"phases":439,"briefSummary":440,"conditions":441,"keywords":442,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":449,"locationsCount":46},"100565525","tpad-for-recovery-of-standing-after-severe-sci-100565525","NCT06643312","TPAD for Recovery of Standing After Severe SCI","Tethered Pelvic Assist Device for Recovery of Standing After Severe SCI","Inclusion Criteria:\n\n1. At least 18 years of age at the time of enrollment;\n2. stable medical condition\n3. at least one year post-spinal cord injury (Groups 1-4)\n4. non-progressive, traumatic SCI above T10 (Groups 1-4)\n5. Injury Grade A, B, C or D (Groups 1-4)\n6. ability to stand independently for short periods of time, not exceeding 1 hour (Groups 1 and 3)\n7. inability to stand independently (Groups 2 and 4)\n\nExclusion Criteria:\n\n1. unwillingness to wean from anti-spasticity medications;\n2. untreated painful musculoskeletal dysfunction, unhealed fracture, contracture, pressure sore or urinary tract infection\n3. history of bone disease unassociated with decreased bone mineral density due to spinal cord injury\n4. ongoing drug abuse\n5. untreated psychiatric disorders or clinical depression\n6. received botox injections in lower extremities in the prior six months\n7. Cardiopulmonary disease that may interfere with assessments\n8. Untreated severe and persistent dysautonomia\n9. Neurological injury or disease (Group 5)\n10. Orthopedic injury or condition (Group 5)",{"count":216,"type":21},[96],"The purpose of this study is to investigate how standing and sitting balance control is altered after spinal cord injury (SCI) and how a new type of robotic assistive device may be used to improve muscle function. This device is called the Tethered Pelvic Assist Device, or TPAD.\n\nThe main aims are to:\n\n1\\. Examine muscle activation patterns generated during different types of standing in spinal cord injured individuals using robotic assistance or self-assistance for balance\n\n2 and 3. Examine the effectiveness of robotic-assisted stand training in the improvement of posture control during different types of standing and sitting in spinal cord injured individuals.\n\nParticipants will be placed into one of 5 groups based on a physical classification of their spinal cord injury:\n\nGroup 1:\n\n* Individuals with SCI that can stand independently\n* Will receive TPAD training\n* Will undergo standing, posture, sitting, and stepping assessments\n* Participation in this group will last about six months\n\nGroup 2:\n\n* Individuals with SCI that cannot stand independently\n* Will receive TPAD training\n* Will undergo standing, posture, sitting, and stepping assessments\n* Participation in this group will last about 6 months\n\nGroup 3:\n\n* Individuals with SCI that can stand independently\n* Will undergo standing and posture assessments\n* Participation in this group will last about 2 weeks\n\nGroup 4:\n\n* Individuals with SCI that cannot stand independently\n* Will undergo standing and posture assessments\n* Participation in this group will last about 2 weeks\n\nGroup 5:\n\n* Individuals without a SCI\n* Will undergo standing, posture, and sitting assessments\n* Participation in this group will last about 2 weeks",[28],[423],"2024-12-11",{"date":445,"type":38},"2024-12-16",{"date":447,"type":38},"2024-10-22",{"date":80,"type":21},{"name":323,"class":45},{"id":451,"slug":452,"hasResults":11,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":145,"sex":16,"minAge":457,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":22,"phases":460,"briefSummary":461,"conditions":462,"keywords":463,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":46},"100561900","effect-of-tscs-on-ankle-movement-training-in-individuals-with-sci-100561900","NCT06596174","Effect of tSCS on Ankle Movement Training in Individuals With SCI","Effect of tSCS on Ankle Movement Training - Evidence From Spinal Circuitry Adaptation in Individuals With SCI","Health subjects:\n\nExclusion Criteria:\n\n1. Musculoskeletal injuries on legs.\n2. Osteoporosis.\n\nSCI subjects:\n\nInclusion Criteria\n\n1\\. Participants with chronic spinal cord injury, with injury duration greater than one year.\n\nExclusion Criteria\n\n1. Current musculoskeletal or joint injuries in the lower limbs.\n2. History of central or peripheral neuromuscular diseases.\n3. Presence of a pacemaker.\n4. Current use of antispastic or antidepressant medications.\n5. Current venous thromboembolism or osteoporosis.\n6. Impairment of the soleus H-reflex arc.","20 Years",{"count":459,"type":21},80,[96],"This clinical trial explores the effectiveness of transcutaneous spinal cord stimulation (tSCS), a non-invasive technique, in facilitating spinal circuitry adaptation in individuals with spinal cord injury (SCI). While epidural spinal cord stimulation (eSCS) has shown functional benefits, its application is limited by the side effects associated with implanted electrodes. tSCS, which shares a similar mechanism but does not require surgery, has yet to be extensively studied in large human trials.\n\nThe study aims to:\n\nDetermine optimal tSCS parameters for non-invasive spinal stimulation. Investigate the priming effect of tSCS on spinal circuitry during machine-assisted ankle movement training.\n\nExamine the long-term clinical outcomes of combining tSCS with ankle movement training in individuals with incomplete SCI.\n\nThe trial will include both healthy participants and individuals with complete and incomplete SCI, using the soleus post-activation depression (PAD) model to evaluate spinal circuitry adaptation. The results will provide insights into spinal re-adaptation and potentially introduce a novel, non-invasive approach for SCI rehabilitation.",[28],[464,465,466],"post activation depression","transcutaneous spinal cord electrical stimulation (tSCS)","machine-assist therapy","2024-11-24",{"date":469,"type":38},"2024-11-26",{"date":471,"type":38},"2024-11-25",{"date":473,"type":21},"2026-08",{"name":475,"class":45},"Chang Gung University",{"id":477,"slug":478,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":145,"sex":16,"minAge":457,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":22,"phases":485,"briefSummary":486,"conditions":487,"keywords":489,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":498,"leadSponsor":499,"locationsCount":46},"100561901","differential-assessment-of-hypertonia-100561901","NCT06596187","Differential Assessment of Hypertonia","Differential Assessment of Hypertonia Related to CNS Impairment","Health subjects:\n\nExclusion Criteria:\n\n1. Musculoskeletal injuries on legs.\n2. Osteoporosis.\n\nSCI subjects:\n\nInclusion Criteria 1. Participants with chronic spinal cord injury, with injury duration greater than one year.\n\nExclusion Criteria\n\n1. Current musculoskeletal or joint injuries in the lower limbs.\n2. History of central or peripheral neuromuscular diseases.\n3. Presence of a pacemaker.\n4. Current use of antispastic or antidepressant medications.\n5. Current venous thromboembolism or osteoporosis.\n6. Impairment of the soleus H-reflex arc.\n\nPD subjects:\n\nInclusion Criteria:\n\n\\- Clinical diagnosis of Parkinson disease.\n\nExclusion Criteria:\n\n1. Musculoskeletal injuries on legs\n2. Osteoporosis.\n3. Any peripheral or central nervous system injury or disease patients.",{"count":484,"type":21},45,[96],"Spasticity and rigidity are common symptoms of central nervous system injuries, such as spinal cord injury and Parkinson's disease, and result in distinct patterns of increased resistance during passive joint movements. Spasticity is characterized by a velocity-dependent increase in stretch reflexes, accompanied by exaggerated tendon responses, while rigidity is marked by consistent resistance throughout the range of motion, traditionally considered independent of stretch velocity. However, recent studies suggest that rigidity may also be influenced by stretch velocity. This study aims to investigate muscle tone by examining spasticity, rigidity, and normal muscle function through neural and biomechanical changes. Standard clinical tools, such as the Modified Ashworth Scale and Unified Parkinson's Disease Rating Scale, along with additional assessments like the Myoton and Post-Activation Depression (PAD), will be employed.",[28,488],"PD - Parkinson's Disease",[490,491,492,493],"Spasticity","Post activation depression","Passive motion device (CPM)","Rigidity","2024-10-09",{"date":496,"type":38},"2024-10-15",{"date":494,"type":38},{"date":473,"type":21},{"name":475,"class":45},{"id":501,"slug":502,"hasResults":11,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":11,"sex":16,"minAge":507,"maxAge":508,"enrollmentInfo":509,"targetDuration":4,"studyType":22,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":46},"100516136","safety-feasibility-and-efficacy-of-tscs-on-stabilizing-blood-pressure-for-acute-inpatients-with-sci-100516136","NCT06000592","Safety, Feasibility, and Efficacy of TSCS on Stabilizing Blood Pressure for Acute Inpatients With SCI","Safety, Feasibility, and Efficacy of Transcutaneous Spinal Cord Stimulation on Stabilizing Blood Pressure for Acute Inpatients With Spinal Cord Injury","Inclusion Criteria:\n\n* Newly injured patients with traumatic SCI\n* Admitted to Acute Inpatient Rehabilitation at Mount Sinai\n* Within one year of SCI\n* Seated hypotension (systolic BP ≤ 110 mmHg for males or ≤ 100 mmHg for females)\n* Orthostatic hypotension (fall in systolic BP ≥ 20 mmHg and\u002For a fall in diastolic BP ≥ 10 mmHg within 10 minutes of assuming an upright position)\n* Daily fluctuation in systolic BP ≥ 20 mmHg and\u002For fluctuation in diastolic BP ≥ 10 mmHg\n* At least 14 years old\n\nExclusion Criteria:\n\n* Implanted brain\u002Fspine\u002Fnerve stimulators\n* Cochlear implants\n* Cardiac pacemaker\u002Fdefibrillator, or intracardiac lines\n* Open skin lesions on or near the electrode placement sites (neck, upper back)\n* Significant coronary artery or cardiac conduction disease\n* Recent history of myocardial infarction\n* Insufficient mental capacity to understand and independently provide consent\n* Pregnancy\n* Cancer\n* Deemed unsuitable by study physician","14 Years","100 Years",{"count":216,"type":21},[96],"Current forms of pharmacologic and non-pharmacologic treatments for hypotension and orthostatic hypotension (OH) remain inadequate during acute inpatient rehabilitation (AIR) following a traumatic spinal cord injury (SCI). A critical need exists for the identification of safe, practical, and effective treatment options that stabilize blood pressure (BP) after traumatic SCI. Recent published evidence suggests that transcutaneous Spinal Cord Stimulation (TSCS) can be used to raise seated BP, and mitigate the falls in BP during orthostatic repositioning in individuals with chronic SCI. This site-specific project will focus on the use of TSCS to stabilizing seated BP and mitigate the fall in BP during orthostatic repositioning during AIR following traumatic SCI.",[513,514,515,516,177,28,517,518],"Acute Spinal Cord Injury","Spinal Cord Injuries","Neuromodulation","Traumatic Spinal Cord Injury","Blood Pressure","Blood Pressure Disorders","2024-04-01",{"date":521,"type":38},"2024-04-02",{"date":523,"type":38},"2022-01-01",{"date":525,"type":21},"2026-10-01",{"name":527,"class":528},"Jill M. Wecht, Ed.D.","FED"]